Pre-made Sarilumab biosimilar ( Whole mAb, anti-IL6R therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-507
Anti-IL6R therapeutic antibody (Pre-made Sarilumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor. Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IL6R therapeutic antibody (Pre-made Sarilumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Asahi Kasei Pharma Corp;Regeneron Pharmaceuticals;Sanofi|
|Conditions Approved||Rheumatoid arthritis|
|Conditions Active||Juvenile rheumatoid arthritis|
|Conditions Discontinued||Ankylosing spondylitis;COVID-19;Giant cell arteritis;Polymyalgia rheumatica;Uveitis|
|Development Tech||VelocImmune Mouse|